Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
30 participants
OBSERVATIONAL
2017-05-01
2022-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarker Study of Pancreatic Neuroendocrine Tumours
NCT03741517
Studying Biomarkers in Patients With Pancreatic Cancer
NCT00900003
Perfusion Assessment With Contrast-Enhanced EUS in Locally Advanced and Metastatic Pancreatic Cancer
NCT03513198
Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx
NCT00767273
Gene Expression in Pancreatic Cancer
NCT03531125
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Core Needle Biopsy
Core Needle Biopsy is performed from liver metastasis.
Computed Tomography
Computed Tomography
18F-FDG-PET
18F Fluorodeoxyglucose Positron emission tomography
Phlebotomy
3 EDTA tubes drawn from peripheral vein
Molecular genetic analysis
Performed on biomaterial from peripheral vein and core needle biopsy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent
* WHO performance status ≤2
* Progressive disease (as defined by the local investigator) or newly diagnosed disease (defined as prior to medical or oncological intervention except for somatostatin analogue treatment).
* Pathology confirmed diagnosis of pancreatic or duodenal neuroendocrine tumour WHO G1-G3.
o Exception: In newly diagnosed patients with high suspicion of PNET based on clinical and radiological parameters where tissue sample have not yet been obtained. These patients may be included and subsequently excluded if pathology cannot confirm NET.
* Biopsy procedure not associated with inappropriate risk as determined by the responsible physician.
Exclusion Criteria
* Permanent risk factors for biopsy
* Long term treatment with anticoagulant that cannot be temporarily paused without unacceptable risk.
* Permanent coagulation disorder
* Pregnancy or no contraceptive in fertile women.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Uppsala University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Barbro Eriksson
Professor, Senior Attending
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Barbro Eriksson, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Akademiska Sjukhuset, Uppsala
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Akademiska Sjukhuset
Uppsala, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Uppsala University Hospital
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.